Poly Medicure Q1 FY27 Consolidated Revenue Surges 30.3% to ₹525.4 Crore
Poly Medicure reported a 30.3% YoY increase in consolidated revenue to ₹525.4 crore for Q1 FY27. Domestic revenue grew 16.2% and international revenue rose 36.7%. Consolidated EBITDA margin was 24.1%, while standalone EBITDA margin reached 28.0%. The company launched six new products and appointed new CEOs for India/APAC and Brazil operations.
The significant year-on-year revenue growth, margin expansion, and strategic appointments indicate a strong performance and positive future outlook for the company, which is likely to impact investor sentiment and the company's valuation.
The company reported strong revenue growth, improved gross profit margins, and exceeded guidance for standalone EBITDA margin. New product launches and key management appointments also contribute to a positive outlook.
Poly Medicure Limited has announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a significant consolidated revenue growth of 30.3% year-on-year, reaching ₹525.4 crore. Domestic revenue saw a 16.2% increase, while international revenue grew by an impressive 36.7% year-on-year.
The company's gross profit margin improved by 495 basis points to 73.4% on a consolidated basis. Consolidated Operating EBITDA stood at ₹126.7 crore, with a margin of 24.1%, which is within the guided range of 23-25%. Standalone Operating EBITDA was reported at ₹120.8 crore, with a margin of 28.0%, exceeding the guided range of 25%-27%.
Geographically, India contributed ₹146.0 crore, Europe ₹187.3 crore, and RoW ₹188.8 crore to the total consolidated revenue. The revenue mix shows Infusion Therapy accounting for 50% of consolidated revenue, followed by 'Others' at 27%, Cardiology at 11%, Orthopaedics at 9%, and Renal at 5%.
Key business updates include the appointment of Mr. Indranil Mukherjee as CEO for India & APAC and Mr. Renato Rocha as CEO for Polymed Brazil. The company also achieved cumulative stent deployments surpassing 13,000 units and grew dialysis machine installations to approximately 1,100 units. Six new products were launched in Q1 FY27. The company maintained adequate liquidity with ₹854.7 crore in cash and cash equivalents as of June 30, 2026.
What to do with a filing like this
Poly Medicure Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Poly Medicure Limited. Read the original for the full detail.